Karl D Lewis

Karl D Lewis

UNVERIFIED PROFILE

Are you Karl D Lewis?   Register this Author

Register author
Karl D Lewis

Karl D Lewis

Publications by authors named "Karl D Lewis"

Are you Karl D Lewis?   Register this Author

46Publications

6934Reads

23Profile Views

Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.

J Neurooncol 2018 Oct 16;140(1):55-62. Epub 2018 Jun 16.

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2930-5DOI Listing
October 2018

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

Int Immunopharmacol 2018 Oct 16;63:282-291. Epub 2018 Aug 16.

University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA; Division of Surgical Oncology, Department of Surgery, USA; University of Colorado Cancer Center, Aurora, CO, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15675769183038
Publisher Site
http://dx.doi.org/10.1016/j.intimp.2018.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134177PMC
October 2018

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

N Engl J Med 2018 07 4;379(4):341-351. Epub 2018 Jun 4.

From the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston (M.R.M.), and South Texas Accelerated Research Therapeutics (START), San Antonio (K.P.P.) - both in Texas; the Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (D.R., A.A.T.), the Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, VIC (A.G.), the Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA (A.M.L.), and Royal Brisbane and Women's Hospital and University of Queensland, Brisbane (B.G.M.H.) - all in Australia; the Department of Dermatology, Brigham and Women's Hospital (C.D.S.), the Department of Dermatology, Harvard Medical School (C.D.S.), and the Department of Medical Oncology, Dana-Farber Cancer Institute (G.R.) - all in Boston; Schleswig-Holstein University Hospital, Kiel (A.H.), and University Hospital Essen, Essen and German Cancer Consortium, Essen (D.S.) - both in Germany; University of Colorado Denver, School of Medicine, Aurora (K.D.L.); the Departments of Head and Neck-Endocrine Oncology (C.H.C.) and Cutaneous Oncology (N.I.K.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; the Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis (L.H.-A.); the Department of Dermatology, Stanford University School of Medicine, Redwood City (A.L.S.C.), and the Division of Dermatology, City of Hope, Duarte (B.M.) - both in California; the Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York (L.A.D.), and Regeneron Pharmaceuticals, Tarrytown (F.S., M.M., K.M., G.D.Y., I.L., M.G.F.) - both in New York; Regeneron Pharmaceuticals, Basking Ridge, NJ (B.G., S.L., J.L., J.B., E.S.); University of Arizona Cancer Center, Tucson (H.M.B.), and Banner MD Anderson Cancer (J.H.) and the Department of Medical Oncology, Banner MD Anderson Cancer Center (J.N.), Gilbert - all in Arizona; Medical Oncology Department, Vall D'Hebron University Hospital (I.B.), and Institut Català D'Oncologia, Oncobell Program (IDIBELL), L'Hospitalet de Llobregat (M.G.-M.), Barcelona, and START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid (V.M.) - all in Spain; Sarah Cannon Research Institute, Nashville (M.L.J.); and the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta (T.K.O.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805131
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805131DOI Listing
July 2018

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.

Melanoma Res 2017 06;27(3):189-199

aDepartment of Medicine, Division of Medical Oncology bDepartment of Pathology cDepartment of Surgery, School of Medicine dDepartment of Biostatistics and Informatics, Colorado School of Public Health eUniversity of Colorado Cancer Center fDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470740PMC
June 2017

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib.

Onco Targets Ther 2016 22;9:3739-52. Epub 2016 Jun 22.

Cutaneous Oncology Program, Division of Medical Oncology, School of Medicine, University of Colorado - Anschutz Medical Campus, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S86774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922803PMC
July 2016

Dermatofibrosarcoma protuberans, version 1.2014.

J Natl Compr Canc Netw 2014 Jun;12(6):863-8

From University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; Roswell Park Cancer Institute; UC San Diego Moores Cancer Center; Moffitt Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Colorado Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The University of Texas MD Anderson Cancer Center; Duke Cancer Institute; Fox Chase Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; University of Alabama at Birmingham Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Dana-Farber/Brigham and Women's Cancer Center; Vanderbilt-Ingram Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0081DOI Listing
June 2014

Anti-CTLA4 antibody therapy related complications on FDG PET/CT.

Clin Nucl Med 2014 Jan;39(1):e93-6

From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0b013e318292a775DOI Listing
January 2014

Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.

J Invest Dermatol 2012 Oct 24;132(10):2440-2450. Epub 2012 May 24.

Department of Dermatology, University of Colorado Denver, Aurora, Colorado, USA; Charles C Gates Regenerative Medicine and Stem Cell Biology, University of Colorado Denver, Aurora, Colorado, USA; Denver Veterans Affairs Medical Center, Denver, Colorado, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434242PMC
October 2012

Therapeutic options in cutaneous melanoma: latest developments.

Ther Adv Med Oncol 2011 Sep;3(5):245-51

Department of Hematology/Oncology, University of Colorado at Denver, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834011415308
Publisher Site
http://dx.doi.org/10.1177/1758834011415308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169931PMC
September 2011

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review.

Core Evid 2010 Oct 21;5:39-48. Epub 2010 Oct 21.

Division of Medical Oncology, Department of Cutaneous Oncology, University of Colorado, Denver, CO, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963921PMC
October 2010

Increased survival from stage IV melanoma associated with fewer regulatory T Cells.

J Surg Res 2009 Jun 2;154(1):13-20. Epub 2008 Jun 2.

Department of Surgery, University of Colorado Denver, Denver, Colorado 80262, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00224804080034
Publisher Site
http://dx.doi.org/10.1016/j.jss.2008.04.043DOI Listing
June 2009

Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.

Int J Dermatol 2009 Apr;48(4):426-30

Department of Dermatology and Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010-7163, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-4632.2009.03987.xDOI Listing
April 2009

PI-88: a novel inhibitor of angiogenesis.

Expert Opin Investig Drugs 2008 Nov;17(11):1769-76

University of Colorado Cancer Center, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.11.1769DOI Listing
November 2008

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

Invest New Drugs 2008 Feb 20;26(1):89-94. Epub 2007 Sep 20.

Cutaneous Oncology Program, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-007-9080-5DOI Listing
February 2008

Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass.

Oncology (Williston Park) 2006 Jun;20(7):763-70

Division of Medical Oncology, Cutaneous Oncology Program, University of Colorado Cancer Center, Denver, Colorado, USA.

View Article

Download full-text PDF

Source
June 2006

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Invest New Drugs 2006 Jan;24(1):89-94

University of Colorado, Cancer Center, 1665 North Ursula St, Mail Stop F-703, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-005-4544-yDOI Listing
January 2006